Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925260 | 0.97 | CYP3A4 (0.51) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL2007741 | 0.93 | OPRM1 (0.45) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL19410760 | 0.92 | CYP3A4 (0.44) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL1684100 | 0.88 | OPRM1 (0.48) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL9013443 | 0.88 | CYP3A4 (0.55) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL1311224 | 0.87 | CYP3A4 (0.52) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL1282252 | 0.87 | OPRM1 (0.47) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL23225661 | 0.86 | CYP3A4 (0.61) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL5729678 | 0.86 | CYP3A4 (0.53) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL12571554 | 0.84 | CYP2D6 (0.44) | CYP3A4ABCB11LMNACYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| EP-2086939-B8 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2233480-A1 | Chemical compounds | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| EP-2086939-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | AstraZeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312372-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | CYP3A4 30/4885ABCB11 178/4885LMNA 3702/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | CYP3A4 30/4885ABCB11 178/4885LMNA 3702/4885 |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | CYP3A4 30/4885ABCB11 178/4885LMNA 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.